Fortress Biotech, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Fortress Biotech, Inc. on June 17, 2025. The meeting was conducted virtually and addressed five key proposals regarding corporate governance, auditor ratification, executive compensation, and charter amendments.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding stockholder voting results and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following outcomes were determined by stockholder votes at the annual meeting:
- Director Elections: All seven nominees were elected to the Board of Directors. Total votes cast for each director ranged from approximately 9.18 million to 9.56 million out of 10.92 million total votes.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025, with over 20.4 million votes in favor.
- Executive Compensation (Say-on-Pay): The advisory vote to approve named executive officer compensation passed with approximately 9.39 million votes in favor.
- Compensation Vote Frequency: Stockholders voted to hold advisory votes on executive compensation every three years. The Board confirmed this frequency will apply until the next required vote in 2031.
- Charter Amendment: Stockholders approved the Second Amended and Restated Certificate of Incorporation, which includes provisions for officer exculpation. The proposal received approximately 7.96 million votes in favor.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, risk factors, or contingencies. It strictly reports the administrative outcomes of the annual stockholder meeting.
Key Facts for Investor Verification
- Verify the specific terms of the officer exculpation provision in the Second Amended and Restated Certificate of Incorporation.
- Confirm the composition of the newly elected Board of Directors and their tenure until the 2026 annual meeting.
- Note the decision to conduct Say-on-Pay votes every three years, with the next frequency vote scheduled for 2031.
- Review the definitive proxy statement (Schedule 14A) filed on April 28, 2025, for detailed descriptions of the proposals and director biographies.